All Updates

All Updates

icon
Filter
Funding
Formation Bio raises USD 372 million in Series D funding to expand clinical portfolio and advance AI drug development
AI Drug Discovery
Jun 26, 2024
Last week:
Product updates
Eve Air Mobility unveils unmanned eVTOL prototype
Passenger eVTOL Aircraft
Yesterday
Product updates
Lilium advances POWER-ON, providing solutions with leading digital innovators
Passenger eVTOL Aircraft
Yesterday
Industry news
New South Korean space agency provides rundown of plans
Space Travel and Exploration Tech
Jul 20, 2024
Management news
Bionano Genomics receives Nasdaq non-compliance notice; continues trading efforts
Precision Medicine
Jul 19, 2024
Funding
GRO Biosciences raises USD 60.3 million in Series B funding to advance lead program into clinical trials and expand GRObio pipeline
Precision Medicine
Jul 19, 2024
Management news
Yooz announces new appointments in C-Suite
Business Expense Management
Jul 19, 2024
Regulation/policy
Airwallex secures license to expand retail investment offerings in Australia
FinTech Infrastructure
Jul 19, 2024
Partnerships
EHang collaborates with KC Smart Mobility to expand EH216-S sales and operations in China
Passenger eVTOL Aircraft
Jul 19, 2024
Industry news
China launches Gaofen-11 high-resolution intelligence satellite
Satellite Management
Jul 19, 2024
Industry news
France funds miniature satellite capture and inspection mission
Satellite Management
Jul 19, 2024
AI Drug Discovery

AI Drug Discovery

Jun 26, 2024

Formation Bio raises USD 372 million in Series D funding to expand clinical portfolio and advance AI drug development

Funding

  • AI-powered pharmaceutical company Formation Bio has raised USD 372 million in a Series D funding round led by Andreessen Horowitz (a16z), with participation from investors including Sanofi, Sequoia, Angel Growth, FPV Ventures, and more.

  • The proceeds will be allocated to the company’s strategies of acquiring and in-licensing clinical-stage assets from other biotech and pharma companies and enhancing its AI capabilities within drug development and clinical trials.

  • Formation Bio, formerly TrialSpark, accelerates drug development through a proprietary platform based on modern data, LLMs, AI agents, and other technology. The company acquires clinical-stage drugs from pharmaceutical companies, universities, and biotech firms and leverages its AI platform to develop these assets into commercialization.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.